|
| 35976415 | A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer. | Cancer Immunol Immunother | 2023 |
| 38061007 | Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer. | JCO Precis Oncol | 2023 |
| 37686693 | Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling. | Cancers (Basel) | 2023 |
| 37119523 | Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. | Cancer Med | 2023 |
| 36983083 | A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer. | Int J Mol Sci | 2023 |
| 37178439 | mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer. | Mol Oncol | 2023 |
| 37400554 | The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies. | Sci Rep | 2023 |
| 37031196 | Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. | Nat Commun | 2023 |
| 37260332 | A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. | Oncologist | 2023 |
| 36209982 | Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials. | Ann Oncol | 2023 |
| 34615718 | Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35775194 | Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. | Clin Cancer Res | 2022 |
| 35710239 | Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial). | BMJ Open | 2022 |
| 35606463 | Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. | Br J Cancer | 2022 |
| 35669415 | Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer. | Front Oncol | 2022 |
| 35717359 | Reply to Yuxuan Song, Caipeng Qin, and Tao Xu's Letter to the Editor re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331-6. | Eur Urol | 2022 |
| 36481665 | Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. | Nat Commun | 2022 |
| 36147916 | Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study. | Front Oncol | 2022 |
| 36139564 | Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients. | Cancers (Basel) | 2022 |
| 35895277 | Influence of Darolutamide on Cabazitaxel Systemic Exposure. | Clin Pharmacokinet | 2022 |
| 36323051 | CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients. | Eur J Cancer | 2022 |
| 35046062 | Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. | Clin Cancer Res | 2022 |
| 35181986 | Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. | Mol Oncol | 2022 |
| 35086719 | Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. | Eur Urol | 2022 |
| 35326653 | Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing. | Cancers (Basel) | 2022 |
| 34615720 | Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells. | Clin Cancer Res | 2022 |
| 33119892 | Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients. | Clin Pharmacol Ther | 2021 |
| 33571468 | SARS-CoV-2 vaccination and phase 1 cancer clinical trials. | Lancet Oncol | 2021 |
| 33761899 | Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. | BMC Cancer | 2021 |
| 33556368 | Validation of circulating steroid hormone measurements across different matrices by liquid chromatography-tandem mass spectrometry. | Steroids | 2021 |
| 33495476 | Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. | Nat Commun | 2021 |
| 34409743 | Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer. | J Thromb Haemost | 2021 |
| 34670587 | High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments. | Clin Epigenetics | 2021 |
| 34518310 | A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. | Clin Cancer Res | 2021 |
| 34749299 | Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. | EBioMedicine | 2021 |
| 34422118 | Circulating <i>TP53</i> mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. | Ther Adv Med Oncol | 2021 |
| 34132450 | A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. | Oncologist | 2021 |
| 34045764 | Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. | Nat Genet | 2021 |
| 34326338 | The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. | Nat Commun | 2021 |
| 33965892 | Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: A systematic review. | Cancer Treat Rev | 2021 |
| 34039979 | Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. | Nat Commun | 2021 |
| 33932725 | Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. | Eur J Cancer | 2021 |
| 34006333 | Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients. | Genome Med | 2021 |
| 34359641 | Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634. | Cancers (Basel) | 2021 |
| 34337548 | Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. | Eur Urol Open Sci | 2021 |
| 34373653 | Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. | Nat Med | 2021 |
| 33974560 | 11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration. | JCI Insight | 2021 |
| 31395751 | Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. | Oncologist | 2020 |
| 31667659 | Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). | Invest New Drugs | 2020 |
| 32024849 | A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. | Nat Commun | 2020 |